Great posts @stockrock@dalts66 and others..
Since I first watched the investor presentation in November last year, I have had the impression PH has found something special in CHM-1101 with his sharp connections once again. This molecule, 8 years in development under city of hope was snatched by Paul Hopper before any big Pharma or other small cap bio’s could get their mits on it. Around this time I did a fair amount of research along with finding some very interesting YouTube videos out of city of hope showing the excitement of the pre clinical work. Most of these have been taken down now due to the market sensitive nature, forward looking statements ettc etc after licensing by CHM.
We have seen some key strategy in the Scientific advisory board structure recently in the appointment of DR Yi Lin to the Cellular Immunotherapy Scientific advisory board. This creation of two clear SAB’s allows Christine Brown to focus on CHM-1101 as the Glioblastoma Scientific advisory board chair. This to me is a clear indication of the confidence in CHM-1101 and its quick route (as described by dalts in other posts) to FDA approval. And, as Stock rock pointed out in another thread, the addition of further Cell therapies in next generation programs like NK-Cells (natural killer) and Macrophages or what ever else PH has up his sleeve. In a recent investor interview Leslie Chong (IMU and also on CHM board + a Gioblastoma expert) was asked in the questions what is the difference between IMU and CHM. She stated words to the affect that IMU will be the oncolytic virus focused company and CHM will be Cell therapy focused company……Of course with IMU there will be collaborations with their oncolytic viruses with other cell therapy companies. But, this tells me any further Cell therapy opportunities found by PH will be reside in CHM. The recent change of branding also suggests In my option that CHM will be THE asset rich cell therapy company on the ASX. However I am particularlyexcited about CHM-1101 and its other collaborations. Such amazing work by Michael Barish, Christine Brown and Dongrui Wang.
I was originally here for just for CHM-1101 but with many shots on goal this is shaping up to be another Kite Thereputics success story. It has a fast tracked clinical development road. All the IP is CHM’s, the scientists management and City of Hope are handsomely incentivised and included in its success. That is the beauty of a Paul Hopper built company its respectful and the team is recognised. Management and experience just does not get better than this..
This was the article I read which forced my hand in a significant investment here earlier this year. https://www.eurekalert.org/news-releases/521877 and the article in the highly respected and prestigious science translational medicine https://www.cityofhope.org/news/from-scorpion-to-immunotherapy.
Only around a month away from Q3 when see the safety readout of the Phase I trials and no doubt some efficacy results for CHM-101. It’s rare you get an opportunity with this sort of timing in a ground breaking Cell therapy leader in the making. To say I’m confident is an understatement. If the trial has been running since 26th February 2020 and the average survival for GBM is 6 months, we will no doubt see the obvious signs of efficacy. If these poor patients at what is referred to as end of rope treatments (where everything else has failed them) are still alive it is a very very good sign. Also, In the event there is a major adverse reaction and deaths occur (from the therapy itself not from disease) the trail is halted and we would have heard about it.
What a rewarding segment of the stock market to invest in and what amazing hope these treatments offer to cancer sufferers. Imagine a world without Chemo and cancer being a minor inconvenience rather than a death sentence! Exciting times ahead. I agree with stockrock. This will make global headlines as the first breakthrough in solid tumours if we see any sort of positive response.. but any CR's and it's going to be a special thing for the world. Especially in the tricky blood brain barrier space.
Note: CHM Director George Matcham picked up $165k of shares on market on 4th August @ 34c if it’s good enough for insiders it was good enough for me continue to top up more there while I still can… and also catch up to his holding on the ground floor 
(20min delay)